Literature DB >> 20682204

Epilepsy: an anticipatory presentation of pediatric Wegener's granulomatosis.

Brooke M Moore1, Steven M Rothman, H Brent Clark, Richard K Vehe, Theresa A Laguna.   

Abstract

Wegener's granulomatosis is a necrotizing, granulomatous vasculitis that primarily affects the respiratory tract and kidneys. It is rare in children. Few pediatric and adult case reports described seizures and central nervous system involvement at initial presentation, and none described central nervous system involvement in the absence of respiratory or renal disease. We describe a 17-year-old girl with secondarily generalized seizures and granulomatous lesions in her brain. Although a systemic inflammatory disorder was suspected, she lacked evidence of pulmonary or renal involvement, so her signs were initially labeled as postinfectious encephalitis or variant acute disseminated encephalomyelitis. After 1 year of immunosuppressive therapy, she developed additional signs, leading to histologic confirmation on lung biopsy of Wegener's granulomatosis. This case emphasizes the need for close follow-up to monitor the asynchronous development of diagnostic clues when a systemic vasculitis is suspected but cannot be confirmed.

Entities:  

Mesh:

Year:  2010        PMID: 20682204     DOI: 10.1016/j.pediatrneurol.2010.03.014

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

Review 1.  Seizures in steroid-responsive encephalopathy.

Authors:  Xin Xu; Aolei Lin; Xuefeng Wang
Journal:  Neurol Sci       Date:  2020-11-21       Impact factor: 3.307

2.  Pediatric granulomatosis with polyangiitis exhibiting prominent central nervous system symptoms.

Authors:  Tingting Lu; Jian Bao; Dongfang Lin; Hongbing Chen; Wei Qiu; Zhengqi Lu
Journal:  Childs Nerv Syst       Date:  2016-04-11       Impact factor: 1.475

3.  Epilepsy associated with systemic autoimmune disorders.

Authors:  Orrin Devinsky; Adam Schein; Souhel Najjar
Journal:  Epilepsy Curr       Date:  2013-03       Impact factor: 7.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.